[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fjWK-_dxwCe9w85U9P-9bdwdOferSzSAvAYqx9djWYm8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":50,"rows":57},"Aswan University Hospital",[4],95,false,3,2,16284,7,20,[14,17,20,22,25,28,30,32],{"name":15,"count":16},"Cesarean Section Complications",19,{"name":18,"count":19},"IUCD Complication",8,{"name":21,"count":11},"Placenta Previa",{"name":23,"count":24},"Infertility, Female",5,{"name":26,"count":27},"Postoperative Pain",4,{"name":29,"count":8},"Preeclampsia",{"name":31,"count":8},"Pre-Eclampsia",{"name":33,"count":9},"Postpartum Hemorrhage",[35,40,45],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT06537323","Femoral Nerve Block, Periarticular Nerve Group (PENG) Block, and Preoperative IV Fentanyl","2024-11-01","Femoral nerve block with0.25% bupivacaine guided by ultrasound.",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT06583590","Evaluation of Efficacy of Botulinum Toxin A Plus Oral Tadalafil 5 mg in Diabetic Men With Erectile Dysfunction","2025-08-31","Botulinum toxin A",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06787638","Effects of Neostigmine-dose on Diaphragmatic Dynamics","2026-01","full dose of Neostigmine",[51,52,53,54,55,56],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[58,84,102,126,144,167,185,203,239,267,285,311,329,354,381,497,548,615,657,699,750,794,824,850,888,914,947,969,991,1013,1035,1066,1088,1120,1145,1175,1202,1229,1253,1277,1295,1318,1336,1354,1372,1397,1415,1436,1464,1489,1507,1529,1547,1569,1587,1605,1623,1646,1669,1687,1708,1734,1760,1778,1796,1814,1832,1850,1872,1890,1908,1931,1958,1976,1997,2019,2037,2063,2081],{"intervention":44,"totalTrials":59,"cells":60},1,{"EARLY_PHASE1":61,"PHASE1":64,"PHASE2":66,"PHASE3":68,"PHASE4":80,"NA":82},{"trials":62,"activeCount":63},[],0,{"trials":65,"activeCount":63},[],{"trials":67,"activeCount":63},[],{"trials":69,"activeCount":59,"soonestReadout":43},[70],{"nctId":41,"briefTitle":42,"status":71,"phases":72,"primaryCompletion":43,"completion":73,"start":74,"enrollment":75,"conditions":76,"interventions":78},"RECRUITING",[53,54],"2025-12-01","2024-08-01",32,[77],"Erectile Dysfunction With Diabetes Mellitus",[44,79],"Tadalafil 5mg",{"trials":81,"activeCount":63},[],{"trials":83,"activeCount":63},[],{"intervention":79,"totalTrials":59,"cells":85},{"EARLY_PHASE1":86,"PHASE1":88,"PHASE2":90,"PHASE3":92,"PHASE4":98,"NA":100},{"trials":87,"activeCount":63},[],{"trials":89,"activeCount":63},[],{"trials":91,"activeCount":63},[],{"trials":93,"activeCount":59,"soonestReadout":43},[94],{"nctId":41,"briefTitle":42,"status":71,"phases":95,"primaryCompletion":43,"completion":73,"start":74,"enrollment":75,"conditions":96,"interventions":97},[53,54],[77],[44,79],{"trials":99,"activeCount":63},[],{"trials":101,"activeCount":63},[],{"intervention":49,"totalTrials":59,"cells":103},{"EARLY_PHASE1":104,"PHASE1":106,"PHASE2":118,"PHASE3":120,"PHASE4":122,"NA":124},{"trials":105,"activeCount":63},[],{"trials":107,"activeCount":59,"soonestReadout":48},[108],{"nctId":46,"briefTitle":47,"status":109,"phases":110,"primaryCompletion":48,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":116},"NOT_YET_RECRUITING",[52],"2026-04","2025-01-25",50,[115],"Diaphragm Ultrasound",[49,117],"half dose of Neostigmine",{"trials":119,"activeCount":63},[],{"trials":121,"activeCount":63},[],{"trials":123,"activeCount":63},[],{"trials":125,"activeCount":63},[],{"intervention":117,"totalTrials":59,"cells":127},{"EARLY_PHASE1":128,"PHASE1":130,"PHASE2":136,"PHASE3":138,"PHASE4":140,"NA":142},{"trials":129,"activeCount":63},[],{"trials":131,"activeCount":59,"soonestReadout":48},[132],{"nctId":46,"briefTitle":47,"status":109,"phases":133,"primaryCompletion":48,"completion":111,"start":112,"enrollment":113,"conditions":134,"interventions":135},[52],[115],[49,117],{"trials":137,"activeCount":63},[],{"trials":139,"activeCount":63},[],{"trials":141,"activeCount":63},[],{"trials":143,"activeCount":63},[],{"intervention":39,"totalTrials":59,"cells":145},{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":150,"PHASE3":152,"PHASE4":154,"NA":156},{"trials":147,"activeCount":63},[],{"trials":149,"activeCount":63},[],{"trials":151,"activeCount":63},[],{"trials":153,"activeCount":63},[],{"trials":155,"activeCount":63},[],{"trials":157,"activeCount":59,"soonestReadout":38},[158],{"nctId":36,"briefTitle":37,"status":71,"phases":159,"primaryCompletion":38,"completion":160,"start":161,"enrollment":162,"conditions":163,"interventions":164},[56],"2025-03-10","2024-06-01",210,[26],[39,165,166],"PENG block with0.25% bupivacaine guided by ultrasound.","Preoperative IV fentanyl 100microgram",{"intervention":165,"totalTrials":59,"cells":168},{"EARLY_PHASE1":169,"PHASE1":171,"PHASE2":173,"PHASE3":175,"PHASE4":177,"NA":179},{"trials":170,"activeCount":63},[],{"trials":172,"activeCount":63},[],{"trials":174,"activeCount":63},[],{"trials":176,"activeCount":63},[],{"trials":178,"activeCount":63},[],{"trials":180,"activeCount":59,"soonestReadout":38},[181],{"nctId":36,"briefTitle":37,"status":71,"phases":182,"primaryCompletion":38,"completion":160,"start":161,"enrollment":162,"conditions":183,"interventions":184},[56],[26],[39,165,166],{"intervention":166,"totalTrials":59,"cells":186},{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":193,"PHASE4":195,"NA":197},{"trials":188,"activeCount":63},[],{"trials":190,"activeCount":63},[],{"trials":192,"activeCount":63},[],{"trials":194,"activeCount":63},[],{"trials":196,"activeCount":63},[],{"trials":198,"activeCount":59,"soonestReadout":38},[199],{"nctId":36,"briefTitle":37,"status":71,"phases":200,"primaryCompletion":38,"completion":160,"start":161,"enrollment":162,"conditions":201,"interventions":202},[56],[26],[39,165,166],{"intervention":204,"totalTrials":9,"cells":205},"Methotrexate",{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":212,"PHASE4":214,"NA":237},{"trials":207,"activeCount":63},[],{"trials":209,"activeCount":63},[],{"trials":211,"activeCount":63},[],{"trials":213,"activeCount":63},[],{"trials":215,"activeCount":63},[216,228],{"nctId":217,"briefTitle":218,"status":219,"phases":220,"primaryCompletion":221,"completion":222,"start":223,"enrollment":224,"conditions":225,"interventions":227},"NCT05427175","Evaluation of the Effect of Narrowband UVB Versus Methotrexate on Serum Chitotriosidase Level in Psoriasis","UNKNOWN",[55],"2023-07-01","2023-09-15","2022-01-10",30,[226],"Psoriasis",[204],{"nctId":229,"briefTitle":230,"status":219,"phases":231,"primaryCompletion":232,"completion":233,"start":234,"enrollment":224,"conditions":235,"interventions":236},"NCT04811911","Evaluation of the Effect of Narrowband UVB Versus Methotrexate on Serum TWEAK Level in Psoriasis",[55],"2021-09-15","2021-12-15","2020-12-13",[226],[204],{"trials":238,"activeCount":63},[],{"intervention":240,"totalTrials":59,"cells":241},"1gm tranexamic acid",{"EARLY_PHASE1":242,"PHASE1":244,"PHASE2":246,"PHASE3":248,"PHASE4":250,"NA":265},{"trials":243,"activeCount":63},[],{"trials":245,"activeCount":63},[],{"trials":247,"activeCount":63},[],{"trials":249,"activeCount":63},[],{"trials":251,"activeCount":63},[252],{"nctId":253,"briefTitle":254,"status":255,"phases":256,"primaryCompletion":257,"completion":258,"start":259,"enrollment":260,"conditions":261,"interventions":262},"NCT03710330","Tranexamic Acid for the Control of Blood Loss at Elective Cesarean Section","COMPLETED",[55],"2020-03-30","2020-08-01","2018-11-01",360,[15],[263,240,264],"normal saline","0.5 gm tranexamic acid",{"trials":266,"activeCount":63},[],{"intervention":264,"totalTrials":59,"cells":268},{"EARLY_PHASE1":269,"PHASE1":271,"PHASE2":273,"PHASE3":275,"PHASE4":277,"NA":283},{"trials":270,"activeCount":63},[],{"trials":272,"activeCount":63},[],{"trials":274,"activeCount":63},[],{"trials":276,"activeCount":63},[],{"trials":278,"activeCount":63},[279],{"nctId":253,"briefTitle":254,"status":255,"phases":280,"primaryCompletion":257,"completion":258,"start":259,"enrollment":260,"conditions":281,"interventions":282},[55],[15],[263,240,264],{"trials":284,"activeCount":63},[],{"intervention":286,"totalTrials":59,"cells":287},"Lactoferrin",{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":294,"PHASE4":296,"NA":309},{"trials":289,"activeCount":63},[],{"trials":291,"activeCount":63},[],{"trials":293,"activeCount":63},[],{"trials":295,"activeCount":63},[],{"trials":297,"activeCount":63},[298],{"nctId":299,"briefTitle":300,"status":255,"phases":301,"primaryCompletion":302,"completion":303,"start":38,"enrollment":304,"conditions":305,"interventions":307},"NCT06491394","Lactoferrin Effect on Kidney and Heart of Rhabdomyolysis Rats",[55],"2025-03-01","2025-04-01",24,[306],"Rhabdomyolysis",[286,308],"glycerin",{"trials":310,"activeCount":63},[],{"intervention":308,"totalTrials":59,"cells":312},{"EARLY_PHASE1":313,"PHASE1":315,"PHASE2":317,"PHASE3":319,"PHASE4":321,"NA":327},{"trials":314,"activeCount":63},[],{"trials":316,"activeCount":63},[],{"trials":318,"activeCount":63},[],{"trials":320,"activeCount":63},[],{"trials":322,"activeCount":63},[323],{"nctId":299,"briefTitle":300,"status":255,"phases":324,"primaryCompletion":302,"completion":303,"start":38,"enrollment":304,"conditions":325,"interventions":326},[55],[306],[286,308],{"trials":328,"activeCount":63},[],{"intervention":330,"totalTrials":59,"cells":331},"Melatonin",{"EARLY_PHASE1":332,"PHASE1":334,"PHASE2":336,"PHASE3":338,"PHASE4":340,"NA":352},{"trials":333,"activeCount":63},[],{"trials":335,"activeCount":63},[],{"trials":337,"activeCount":63},[],{"trials":339,"activeCount":63},[],{"trials":341,"activeCount":63},[342],{"nctId":343,"briefTitle":344,"status":255,"phases":345,"primaryCompletion":346,"completion":347,"start":74,"enrollment":348,"conditions":349,"interventions":351},"NCT07550751","Optimal Dosage of Melatonin for Preoperative Sedation in FESS",[55],"2025-04-30","2025-10-01",160,[350],"Clinical Trial",[330],{"trials":353,"activeCount":63},[],{"intervention":355,"totalTrials":59,"cells":356},"Isonicotinic Acid",{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":363,"PHASE4":365,"NA":379},{"trials":358,"activeCount":63},[],{"trials":360,"activeCount":63},[],{"trials":362,"activeCount":63},[],{"trials":364,"activeCount":63},[],{"trials":366,"activeCount":63},[367],{"nctId":368,"briefTitle":369,"status":219,"phases":370,"primaryCompletion":371,"completion":372,"start":373,"enrollment":374,"conditions":375,"interventions":377},"NCT04499976","Isonicotinic Acid Hydrazide Pretreatment With Misoprostol Induction of Abortion in First-trimester Missed Miscarriage",[55],"2021-04-30","2021-06-30","2020-09-01",240,[376],"Abortion, Missed",[355,378],"Misoprostol",{"trials":380,"activeCount":63},[],{"intervention":382,"totalTrials":383,"cells":384},"misoprostol",11,{"EARLY_PHASE1":385,"PHASE1":387,"PHASE2":389,"PHASE3":391,"PHASE4":393,"NA":399},{"trials":386,"activeCount":63},[],{"trials":388,"activeCount":63},[],{"trials":390,"activeCount":63},[],{"trials":392,"activeCount":63},[],{"trials":394,"activeCount":63},[395],{"nctId":368,"briefTitle":369,"status":219,"phases":396,"primaryCompletion":371,"completion":372,"start":373,"enrollment":374,"conditions":397,"interventions":398},[55],[376],[355,378],{"trials":400,"activeCount":63},[401,412,423,434,440,452,463,472,480,489],{"nctId":402,"briefTitle":403,"status":219,"phases":404,"primaryCompletion":405,"completion":406,"start":407,"enrollment":408,"conditions":409,"interventions":410},"NCT03774524","Sublingual Misoprostol and Tranexamic Acid in Pregnant Women With Twin Pregnancy Undergoing Cesarean Section",[56],"2020-12-31","2021-03-01","2019-01-01",150,[15],[378,411],"TA",{"nctId":413,"briefTitle":414,"status":255,"phases":415,"primaryCompletion":416,"completion":417,"start":418,"enrollment":260,"conditions":419,"interventions":420},"NCT03708497","Carbetocin Versus Oral Tranexamic Acid Plus, Buccal Misoprostol on Blood Loss After Vaginal Delivery",[56],"2020-05-31","2020-07-01","2018-12-01",[33],[421,422,382],"carbetocin","Tranexamic acid plus misoprostol",{"nctId":424,"briefTitle":425,"status":219,"phases":426,"primaryCompletion":427,"completion":428,"start":373,"enrollment":429,"conditions":430,"interventions":431},"NCT04505943","Vaginal Misoprostol and Dinoprostone and Isonicotinic Acid Hydrazide Prior to Copper Intrauterine Device Insertion",[56],"2021-07-30","2021-09-30",200,[18],[432,433,382],"Isonicotinic Acid Hydrazide","dinoprostine",{"nctId":435,"briefTitle":436,"status":219,"phases":437,"primaryCompletion":372,"completion":427,"start":373,"enrollment":374,"conditions":438,"interventions":439},"NCT04500002","Isonicotinic Acid Hydrazide (INH) Pretreatment With Misoprostol Versus Misoprostol Alone in Missed Abortion",[56],[18],[432,378],{"nctId":441,"briefTitle":442,"status":255,"phases":443,"primaryCompletion":444,"completion":445,"start":446,"enrollment":447,"conditions":448,"interventions":450},"NCT03870256","Oral Tranexamic Acid Plus Sublingual Misoprostol in Atonic Postpartum Hemorrhage",[56],"2021-08-01","2021-09-01","2019-04-01",135,[449],"Post Partum Hemorrhage",[382,451,411],"Carbetocin",{"nctId":453,"briefTitle":454,"status":219,"phases":455,"primaryCompletion":456,"completion":457,"start":458,"enrollment":408,"conditions":459,"interventions":461},"NCT05077540","Oxytocin Versus, Sublingual Misoprostol in the Secondary Prevention of Postpartum Hemorrhage After Vaginal Delivery",[56],"2023-10-31","2023-12-31","2021-11-01",[460],"Labor Complication",[462,382],"oxytocin",{"nctId":464,"briefTitle":465,"status":255,"phases":466,"primaryCompletion":467,"completion":258,"start":418,"enrollment":468,"conditions":469,"interventions":470},"NCT03710317","Carbetocin Versus Buccal Misoprostol Plus IV Tranexamic Acid for Prevention of Postpartum Hemorrhage at Cesarean Section",[56],"2020-05-30",400,[15],[421,471,382],"Tranexamic Acid",{"nctId":473,"briefTitle":474,"status":219,"phases":475,"primaryCompletion":372,"completion":476,"start":373,"enrollment":429,"conditions":477,"interventions":478},"NCT04505917","Vaginal Misoprostol and Dinoprostone Prior to Copper Intrauterine Device Insertion in Women",[56],"2021-08-30",[18],[479,382],"dinoprostol",{"nctId":481,"briefTitle":482,"status":255,"phases":483,"primaryCompletion":484,"completion":485,"start":259,"enrollment":468,"conditions":486,"interventions":487},"NCT03710304","Tranexamic Acid Plus Buccal Misoprostol on Blood Loss During and After Cesarean Delivery",[56],"2020-03-31","2020-06-01",[15],[488,422,382],"Oxytocin",{"nctId":490,"briefTitle":491,"status":219,"phases":492,"primaryCompletion":493,"completion":494,"start":407,"enrollment":408,"conditions":495,"interventions":496},"NCT03774706","Sublingual Misoprostol With or Without Intravenous Tranexamic Acid During Hemorrhagic Cesarean Section",[56],"2021-12-30","2022-01-31",[15],[378,471],{"intervention":451,"totalTrials":498,"cells":499},6,{"EARLY_PHASE1":500,"PHASE1":502,"PHASE2":504,"PHASE3":506,"PHASE4":508,"NA":510},{"trials":501,"activeCount":63},[],{"trials":503,"activeCount":63},[],{"trials":505,"activeCount":63},[],{"trials":507,"activeCount":63},[],{"trials":509,"activeCount":63},[],{"trials":511,"activeCount":63},[512,516,520,528,537,541],{"nctId":413,"briefTitle":414,"status":255,"phases":513,"primaryCompletion":416,"completion":417,"start":418,"enrollment":260,"conditions":514,"interventions":515},[56],[33],[421,422,382],{"nctId":441,"briefTitle":442,"status":255,"phases":517,"primaryCompletion":444,"completion":445,"start":446,"enrollment":447,"conditions":518,"interventions":519},[56],[449],[382,451,411],{"nctId":521,"briefTitle":522,"status":219,"phases":523,"primaryCompletion":524,"completion":525,"start":407,"enrollment":468,"conditions":526,"interventions":527},"NCT03777878","Carbetocin Versus Oxytocin Infusion Plus Tranexamic Acid During Cesarean Section",[56],"2021-03-30","2021-05-01",[15],[451,462,411],{"nctId":529,"briefTitle":530,"status":255,"phases":531,"primaryCompletion":484,"completion":258,"start":532,"enrollment":533,"conditions":534,"interventions":535},"NCT03578263","Carbetocin Versus Oxytocin and Ergometrine for the Prevention of Postpartum Hemorrhage",[56],"2018-04-01",220,[15],[451,462,536],"ergometrine",{"nctId":464,"briefTitle":465,"status":255,"phases":538,"primaryCompletion":467,"completion":258,"start":418,"enrollment":468,"conditions":539,"interventions":540},[56],[15],[421,471,382],{"nctId":542,"briefTitle":543,"status":255,"phases":544,"primaryCompletion":372,"completion":444,"start":446,"enrollment":447,"conditions":545,"interventions":546},"NCT03870503","Carbetocin Versus Oxytocin Plus Sublingual Misoprostol in the Management of Atonic Postpartum Hemorrhage",[56],[33],[462,547,451],"oxytocin plus misoprostol",{"intervention":549,"totalTrials":498,"cells":550},"Topical tranexamic acid",{"EARLY_PHASE1":551,"PHASE1":553,"PHASE2":555,"PHASE3":557,"PHASE4":559,"NA":561},{"trials":552,"activeCount":63},[],{"trials":554,"activeCount":63},[],{"trials":556,"activeCount":63},[],{"trials":558,"activeCount":63},[],{"trials":560,"activeCount":63},[],{"trials":562,"activeCount":63},[563,573,580,589,599,608],{"nctId":564,"briefTitle":565,"status":255,"phases":566,"primaryCompletion":372,"completion":444,"start":567,"enrollment":568,"conditions":569,"interventions":570},"NCT03570710","Reducing Blood Loss During Cesarean Hysterectomy for Placenta Accreta Spectrum",[56],"2018-01-01",80,[15],[571,549,572],"intravenous tranexamic acid","Normal saline",{"nctId":574,"briefTitle":575,"status":255,"phases":576,"primaryCompletion":484,"completion":258,"start":259,"enrollment":577,"conditions":578,"interventions":579},"NCT03706339","Reducing Blood Loss During Cesarean Section by Topical Versus IV Tranexamic Acid",[56],450,[15],[571,549],{"nctId":581,"briefTitle":582,"status":255,"phases":583,"primaryCompletion":584,"completion":585,"start":407,"enrollment":586,"conditions":587,"interventions":588},"NCT03778242","Tranexamic Acid in Pregnant Women Undergoing Cesarean Section.",[56],"2022-03-30","2022-07-01",180,[15],[549,263],{"nctId":590,"briefTitle":591,"status":219,"phases":592,"primaryCompletion":593,"completion":594,"start":418,"enrollment":595,"conditions":596,"interventions":597},"NCT03741075","Topical Tranexamic Acid Plus Bilateral Uterine Artery Ligation During Cesarean Delivery",[56],"2020-11-30","2021-01-01",100,[15],[598],"topical tranexamic acid",{"nctId":600,"briefTitle":601,"status":219,"phases":602,"primaryCompletion":603,"completion":604,"start":605,"enrollment":408,"conditions":606,"interventions":607},"NCT05072860","Topical Tranexamic Acid for the Prevention of Postpartum Hemorrhage in Women Undergoing Elective Cesarean Section",[56],"2023-06-30","2023-09-30","2021-10-01",[15],[549],{"nctId":609,"briefTitle":610,"status":219,"phases":611,"primaryCompletion":456,"completion":612,"start":605,"enrollment":408,"conditions":613,"interventions":614},"NCT05072873","Topical Tranexamic Acid for the Prevention of Postpartum Hemorrhage in Women With Twin Pregnancy",[56],"2023-11-30",[15],[549],{"intervention":462,"totalTrials":498,"cells":616},{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":621,"PHASE3":623,"PHASE4":625,"NA":627},{"trials":618,"activeCount":63},[],{"trials":620,"activeCount":63},[],{"trials":622,"activeCount":63},[],{"trials":624,"activeCount":63},[],{"trials":626,"activeCount":63},[],{"trials":628,"activeCount":63},[629,633,641,645,649,653],{"nctId":521,"briefTitle":522,"status":219,"phases":630,"primaryCompletion":524,"completion":525,"start":407,"enrollment":468,"conditions":631,"interventions":632},[56],[15],[451,462,411],{"nctId":634,"briefTitle":635,"status":219,"phases":636,"primaryCompletion":637,"completion":638,"start":373,"enrollment":468,"conditions":639,"interventions":640},"NCT04518176","Bilateral Uterine Artery Ligation During the Cesarean Delivery of Twins",[56],"2022-06-30","2022-08-31",[15],[488],{"nctId":529,"briefTitle":530,"status":255,"phases":642,"primaryCompletion":484,"completion":258,"start":532,"enrollment":533,"conditions":643,"interventions":644},[56],[15],[451,462,536],{"nctId":453,"briefTitle":454,"status":219,"phases":646,"primaryCompletion":456,"completion":457,"start":458,"enrollment":408,"conditions":647,"interventions":648},[56],[460],[462,382],{"nctId":481,"briefTitle":482,"status":255,"phases":650,"primaryCompletion":484,"completion":485,"start":259,"enrollment":468,"conditions":651,"interventions":652},[56],[15],[488,422,382],{"nctId":542,"briefTitle":543,"status":255,"phases":654,"primaryCompletion":372,"completion":444,"start":446,"enrollment":447,"conditions":655,"interventions":656},[56],[33],[462,547,451],{"intervention":411,"totalTrials":24,"cells":658},{"EARLY_PHASE1":659,"PHASE1":661,"PHASE2":663,"PHASE3":665,"PHASE4":667,"NA":669},{"trials":660,"activeCount":63},[],{"trials":662,"activeCount":63},[],{"trials":664,"activeCount":63},[],{"trials":666,"activeCount":63},[],{"trials":668,"activeCount":63},[],{"trials":670,"activeCount":63},[671,675,679,683,691],{"nctId":402,"briefTitle":403,"status":219,"phases":672,"primaryCompletion":405,"completion":406,"start":407,"enrollment":408,"conditions":673,"interventions":674},[56],[15],[378,411],{"nctId":441,"briefTitle":442,"status":255,"phases":676,"primaryCompletion":444,"completion":445,"start":446,"enrollment":447,"conditions":677,"interventions":678},[56],[449],[382,451,411],{"nctId":521,"briefTitle":522,"status":219,"phases":680,"primaryCompletion":524,"completion":525,"start":407,"enrollment":468,"conditions":681,"interventions":682},[56],[15],[451,462,411],{"nctId":684,"briefTitle":685,"status":219,"phases":686,"primaryCompletion":524,"completion":687,"start":446,"enrollment":595,"conditions":688,"interventions":690},"NCT03880604","Triple Tourniquets With or Without Tranexamic Acid for Reducing Blood Loss at Open Myomectomy",[56],"2021-07-01",[689],"Myoma",[411],{"nctId":692,"briefTitle":693,"status":219,"phases":694,"primaryCompletion":593,"completion":695,"start":418,"enrollment":696,"conditions":697,"interventions":698},"NCT03741114","Foley's Catheter Balloon Plus Tranexamic Acid During Cesarean Delivery for Placenta Previa",[56],"2021-02-01",120,[21],[411],{"intervention":700,"totalTrials":24,"cells":701},"INH",{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":708,"PHASE4":710,"NA":739},{"trials":703,"activeCount":63},[],{"trials":705,"activeCount":63},[],{"trials":707,"activeCount":63},[],{"trials":709,"activeCount":63},[],{"trials":711,"activeCount":63},[712,718,724,732],{"nctId":713,"briefTitle":714,"status":255,"phases":715,"primaryCompletion":476,"completion":232,"start":373,"enrollment":408,"conditions":716,"interventions":717},"NCT04500522","Vaginal Isonicotinic Acid Hydrazide Prior to Diagnostic Office Hysteroscopy in Primarily Infertile Patients",[55],[23],[700],{"nctId":719,"briefTitle":720,"status":255,"phases":721,"primaryCompletion":372,"completion":444,"start":373,"enrollment":533,"conditions":722,"interventions":723},"NCT04499989","Vaginal Isonicotinic Acid Hydrazide (INH) Administration Prior to T380A Intrauterine Device Insertion",[55],[18],[700],{"nctId":725,"briefTitle":726,"status":255,"phases":727,"primaryCompletion":728,"completion":729,"start":258,"enrollment":533,"conditions":730,"interventions":731},"NCT04500028","Vaginal Isonicotinic Acid Hydrazide Administration Prior to Insertion Levonorgestrel-releasing Intrauterine System",[55],"2021-10-31","2021-12-01",[18],[700],{"nctId":733,"briefTitle":734,"status":255,"phases":735,"primaryCompletion":372,"completion":476,"start":373,"enrollment":736,"conditions":737,"interventions":738},"NCT04500015","Vaginal Isonicotinic Acid Hydrazide Administration Prior to Intrauterine Device Insertion",[55],130,[18],[700],{"trials":740,"activeCount":63},[741],{"nctId":742,"briefTitle":743,"status":219,"phases":744,"primaryCompletion":493,"completion":745,"start":373,"enrollment":429,"conditions":746,"interventions":748},"NCT04500496","Vaginal Dinoprostone Versus Isonicotinic Acid Hydrazide Prior to Diagnostic Office Hysteroscopy",[56],"2022-01-30",[747],"Postmenopausal Bleeding",[700,749],"dinoprostone",{"intervention":751,"totalTrials":27,"cells":752},"lidocaine patch",{"EARLY_PHASE1":753,"PHASE1":755,"PHASE2":757,"PHASE3":759,"PHASE4":761,"NA":763},{"trials":754,"activeCount":63},[],{"trials":756,"activeCount":63},[],{"trials":758,"activeCount":63},[],{"trials":760,"activeCount":63},[],{"trials":762,"activeCount":63},[],{"trials":764,"activeCount":63},[765,773,779,788],{"nctId":766,"briefTitle":767,"status":219,"phases":768,"primaryCompletion":769,"completion":445,"start":373,"enrollment":429,"conditions":770,"interventions":771},"NCT04517890","Transdermal Lidocaine Administration Prior to Insertion Levonorgestrel-releasing Intrauterine System",[56],"2021-08-31",[18],[751,772],"Sham patch",{"nctId":774,"briefTitle":775,"status":219,"phases":776,"primaryCompletion":372,"completion":769,"start":373,"enrollment":696,"conditions":777,"interventions":778},"NCT04518189","Transdermal Lidocaine for Pain Control During Hysterosalpingography",[56],[23],[751,772],{"nctId":780,"briefTitle":781,"status":219,"phases":782,"primaryCompletion":524,"completion":783,"start":373,"enrollment":586,"conditions":784,"interventions":785},"NCT04505644","Lidocaine Patch Versus Intravenous Lidocaine in Pain Relief After Cesarean Section",[56],"2021-05-30",[15],[751,786,787],"IV lidocaine","IV saline infusion +Sham patch",{"nctId":789,"briefTitle":790,"status":219,"phases":791,"primaryCompletion":769,"completion":428,"start":373,"enrollment":429,"conditions":792,"interventions":793},"NCT04518202","Transdermal Lidocaine for Pain Control During Diagnostic Office Hysteroscopy",[56],[23],[751,772],{"intervention":471,"totalTrials":8,"cells":795},{"EARLY_PHASE1":796,"PHASE1":798,"PHASE2":800,"PHASE3":802,"PHASE4":804,"NA":806},{"trials":797,"activeCount":63},[],{"trials":799,"activeCount":63},[],{"trials":801,"activeCount":63},[],{"trials":803,"activeCount":63},[],{"trials":805,"activeCount":63},[],{"trials":807,"activeCount":63},[808,816,820],{"nctId":809,"briefTitle":810,"status":219,"phases":811,"primaryCompletion":637,"completion":812,"start":373,"enrollment":813,"conditions":814,"interventions":815},"NCT04518163","Bakri Balloon Plus Tranexamic Acid During Cesarean Delivery for Placenta Previa",[56],"2022-07-31",140,[21],[471],{"nctId":464,"briefTitle":465,"status":255,"phases":817,"primaryCompletion":467,"completion":258,"start":418,"enrollment":468,"conditions":818,"interventions":819},[56],[15],[421,471,382],{"nctId":490,"briefTitle":491,"status":219,"phases":821,"primaryCompletion":493,"completion":494,"start":407,"enrollment":408,"conditions":822,"interventions":823},[56],[15],[378,471],{"intervention":772,"totalTrials":8,"cells":825},{"EARLY_PHASE1":826,"PHASE1":828,"PHASE2":830,"PHASE3":832,"PHASE4":834,"NA":836},{"trials":827,"activeCount":63},[],{"trials":829,"activeCount":63},[],{"trials":831,"activeCount":63},[],{"trials":833,"activeCount":63},[],{"trials":835,"activeCount":63},[],{"trials":837,"activeCount":63},[838,842,846],{"nctId":766,"briefTitle":767,"status":219,"phases":839,"primaryCompletion":769,"completion":445,"start":373,"enrollment":429,"conditions":840,"interventions":841},[56],[18],[751,772],{"nctId":774,"briefTitle":775,"status":219,"phases":843,"primaryCompletion":372,"completion":769,"start":373,"enrollment":696,"conditions":844,"interventions":845},[56],[23],[751,772],{"nctId":789,"briefTitle":790,"status":219,"phases":847,"primaryCompletion":769,"completion":428,"start":373,"enrollment":429,"conditions":848,"interventions":849},[56],[23],[751,772],{"intervention":851,"totalTrials":8,"cells":852},"bupivacaine",{"EARLY_PHASE1":853,"PHASE1":855,"PHASE2":857,"PHASE3":859,"PHASE4":861,"NA":863},{"trials":854,"activeCount":63},[],{"trials":856,"activeCount":63},[],{"trials":858,"activeCount":63},[],{"trials":860,"activeCount":63},[],{"trials":862,"activeCount":63},[],{"trials":864,"activeCount":63},[865,873,879],{"nctId":866,"briefTitle":867,"status":255,"phases":868,"primaryCompletion":257,"completion":258,"start":407,"enrollment":696,"conditions":869,"interventions":871},"NCT03767920","Role of Dexamethasone in Transversus Abdominis Plane Block After Cesarean Section",[56],[870],"Cesarean Section",[851,872],"dexamethasone",{"nctId":874,"briefTitle":875,"status":255,"phases":876,"primaryCompletion":257,"completion":258,"start":407,"enrollment":408,"conditions":877,"interventions":878},"NCT03769818","Role of Dexamethasone for Erector Spinae Plane Block in Patients Undergoing Total Abdominal Hysterectomy",[56],[26],[851,872],{"nctId":880,"briefTitle":881,"status":255,"phases":882,"primaryCompletion":883,"completion":258,"start":407,"enrollment":408,"conditions":884,"interventions":885},"NCT03770013","Dexmedetomidine Versus Clonidine for Transversus Abdominis Plane Block in Patients Undergoing Elective Caesarean Section",[56],"2020-06-30",[26],[851,886,887],"Dexmedetomidine","clonidine",{"intervention":263,"totalTrials":8,"cells":889},{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":894,"PHASE3":896,"PHASE4":898,"NA":904},{"trials":891,"activeCount":63},[],{"trials":893,"activeCount":63},[],{"trials":895,"activeCount":63},[],{"trials":897,"activeCount":63},[],{"trials":899,"activeCount":63},[900],{"nctId":253,"briefTitle":254,"status":255,"phases":901,"primaryCompletion":257,"completion":258,"start":259,"enrollment":260,"conditions":902,"interventions":903},[55],[15],[263,240,264],{"trials":905,"activeCount":63},[906,910],{"nctId":564,"briefTitle":565,"status":255,"phases":907,"primaryCompletion":372,"completion":444,"start":567,"enrollment":568,"conditions":908,"interventions":909},[56],[15],[571,549,572],{"nctId":581,"briefTitle":582,"status":255,"phases":911,"primaryCompletion":584,"completion":585,"start":407,"enrollment":586,"conditions":912,"interventions":913},[56],[15],[549,263],{"intervention":915,"totalTrials":9,"cells":916},"Aspirin 162 mg",{"EARLY_PHASE1":917,"PHASE1":919,"PHASE2":921,"PHASE3":923,"PHASE4":925,"NA":927},{"trials":918,"activeCount":63},[],{"trials":920,"activeCount":63},[],{"trials":922,"activeCount":63},[],{"trials":924,"activeCount":63},[],{"trials":926,"activeCount":63},[],{"trials":928,"activeCount":63},[929,939],{"nctId":930,"briefTitle":931,"status":219,"phases":932,"primaryCompletion":933,"completion":934,"start":418,"enrollment":935,"conditions":936,"interventions":937},"NCT03725891","Aspirin for Prevention of Preeclampsia in Healthy, Nulliparous Obese and Overweight Pregnant Women",[56],"2021-11-30","2022-01-01",600,[29],[915,938],"Aspirin 81 mg",{"nctId":940,"briefTitle":941,"status":219,"phases":942,"primaryCompletion":593,"completion":594,"start":418,"enrollment":935,"conditions":943,"interventions":944},"NCT03726177","Aspirin for Prevention of Preeclampsia",[56],[29],[945,946],"aspirin 162 mg","aspirin 81 mg",{"intervention":938,"totalTrials":9,"cells":948},{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":953,"PHASE3":955,"PHASE4":957,"NA":959},{"trials":950,"activeCount":63},[],{"trials":952,"activeCount":63},[],{"trials":954,"activeCount":63},[],{"trials":956,"activeCount":63},[],{"trials":958,"activeCount":63},[],{"trials":960,"activeCount":63},[961,965],{"nctId":930,"briefTitle":931,"status":219,"phases":962,"primaryCompletion":933,"completion":934,"start":418,"enrollment":935,"conditions":963,"interventions":964},[56],[29],[915,938],{"nctId":940,"briefTitle":941,"status":219,"phases":966,"primaryCompletion":593,"completion":594,"start":418,"enrollment":935,"conditions":967,"interventions":968},[56],[29],[945,946],{"intervention":422,"totalTrials":9,"cells":970},{"EARLY_PHASE1":971,"PHASE1":973,"PHASE2":975,"PHASE3":977,"PHASE4":979,"NA":981},{"trials":972,"activeCount":63},[],{"trials":974,"activeCount":63},[],{"trials":976,"activeCount":63},[],{"trials":978,"activeCount":63},[],{"trials":980,"activeCount":63},[],{"trials":982,"activeCount":63},[983,987],{"nctId":413,"briefTitle":414,"status":255,"phases":984,"primaryCompletion":416,"completion":417,"start":418,"enrollment":260,"conditions":985,"interventions":986},[56],[33],[421,422,382],{"nctId":481,"briefTitle":482,"status":255,"phases":988,"primaryCompletion":484,"completion":485,"start":259,"enrollment":468,"conditions":989,"interventions":990},[56],[15],[488,422,382],{"intervention":872,"totalTrials":9,"cells":992},{"EARLY_PHASE1":993,"PHASE1":995,"PHASE2":997,"PHASE3":999,"PHASE4":1001,"NA":1003},{"trials":994,"activeCount":63},[],{"trials":996,"activeCount":63},[],{"trials":998,"activeCount":63},[],{"trials":1000,"activeCount":63},[],{"trials":1002,"activeCount":63},[],{"trials":1004,"activeCount":63},[1005,1009],{"nctId":866,"briefTitle":867,"status":255,"phases":1006,"primaryCompletion":257,"completion":258,"start":407,"enrollment":696,"conditions":1007,"interventions":1008},[56],[870],[851,872],{"nctId":874,"briefTitle":875,"status":255,"phases":1010,"primaryCompletion":257,"completion":258,"start":407,"enrollment":408,"conditions":1011,"interventions":1012},[56],[26],[851,872],{"intervention":571,"totalTrials":9,"cells":1014},{"EARLY_PHASE1":1015,"PHASE1":1017,"PHASE2":1019,"PHASE3":1021,"PHASE4":1023,"NA":1025},{"trials":1016,"activeCount":63},[],{"trials":1018,"activeCount":63},[],{"trials":1020,"activeCount":63},[],{"trials":1022,"activeCount":63},[],{"trials":1024,"activeCount":63},[],{"trials":1026,"activeCount":63},[1027,1031],{"nctId":564,"briefTitle":565,"status":255,"phases":1028,"primaryCompletion":372,"completion":444,"start":567,"enrollment":568,"conditions":1029,"interventions":1030},[56],[15],[571,549,572],{"nctId":574,"briefTitle":575,"status":255,"phases":1032,"primaryCompletion":484,"completion":258,"start":259,"enrollment":577,"conditions":1033,"interventions":1034},[56],[15],[571,549],{"intervention":1036,"totalTrials":9,"cells":1037},"lidocaine",{"EARLY_PHASE1":1038,"PHASE1":1040,"PHASE2":1042,"PHASE3":1044,"PHASE4":1046,"NA":1048},{"trials":1039,"activeCount":63},[],{"trials":1041,"activeCount":63},[],{"trials":1043,"activeCount":63},[],{"trials":1045,"activeCount":63},[],{"trials":1047,"activeCount":63},[],{"trials":1049,"activeCount":63},[1050,1059],{"nctId":1051,"briefTitle":1052,"status":255,"phases":1053,"primaryCompletion":372,"completion":1054,"start":373,"enrollment":408,"conditions":1055,"interventions":1056},"NCT04505657","Lidocaine Spray Plus Oral Celecoxib for Pain Control During Hysterosalpingography",[56],"2021-09-27",[18],[1057,1058,1036],"celecoxib plus lidocaine","Celecoxib",{"nctId":1060,"briefTitle":1061,"status":255,"phases":1062,"primaryCompletion":257,"completion":258,"start":418,"enrollment":696,"conditions":1063,"interventions":1065},"NCT03748108","Bolus Administration of Intravenous Lidocaine at the Time of Abdominal Hysterectomy",[56],[1064],"Abdominal Hysterectomy",[1036],{"intervention":432,"totalTrials":9,"cells":1067},{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1072,"PHASE3":1074,"PHASE4":1076,"NA":1078},{"trials":1069,"activeCount":63},[],{"trials":1071,"activeCount":63},[],{"trials":1073,"activeCount":63},[],{"trials":1075,"activeCount":63},[],{"trials":1077,"activeCount":63},[],{"trials":1079,"activeCount":63},[1080,1084],{"nctId":424,"briefTitle":425,"status":219,"phases":1081,"primaryCompletion":427,"completion":428,"start":373,"enrollment":429,"conditions":1082,"interventions":1083},[56],[18],[432,433,382],{"nctId":435,"briefTitle":436,"status":219,"phases":1085,"primaryCompletion":372,"completion":427,"start":373,"enrollment":374,"conditions":1086,"interventions":1087},[56],[18],[432,378],{"intervention":1089,"totalTrials":9,"cells":1090},"17-OHPC",{"EARLY_PHASE1":1091,"PHASE1":1093,"PHASE2":1095,"PHASE3":1097,"PHASE4":1099,"NA":1101},{"trials":1092,"activeCount":63},[],{"trials":1094,"activeCount":63},[],{"trials":1096,"activeCount":63},[],{"trials":1098,"activeCount":63},[],{"trials":1100,"activeCount":63},[],{"trials":1102,"activeCount":63},[1103,1112],{"nctId":1104,"briefTitle":1105,"status":219,"phases":1106,"primaryCompletion":1107,"completion":1108,"start":407,"enrollment":468,"conditions":1109,"interventions":1110},"NCT03779451","Vaginal Progesterone Versus 17-Alpha-Hydroxyprogesterone Caproate in Placenta Previa",[56],"2021-12-31","2022-04-01",[21],[1089,1111],"vaginal progesterone",{"nctId":1113,"briefTitle":1114,"status":219,"phases":1115,"primaryCompletion":1107,"completion":1116,"start":407,"enrollment":1117,"conditions":1118,"interventions":1119},"NCT03779438","17-Alpha-Hydroxyprogesterone Caproate in Pregnant Women With Placenta Previa",[56],"2022-03-01",300,[21],[1089],{"intervention":1111,"totalTrials":9,"cells":1121},{"EARLY_PHASE1":1122,"PHASE1":1124,"PHASE2":1126,"PHASE3":1128,"PHASE4":1130,"NA":1132},{"trials":1123,"activeCount":63},[],{"trials":1125,"activeCount":63},[],{"trials":1127,"activeCount":63},[],{"trials":1129,"activeCount":63},[],{"trials":1131,"activeCount":63},[],{"trials":1133,"activeCount":63},[1134,1138],{"nctId":1104,"briefTitle":1105,"status":219,"phases":1135,"primaryCompletion":1107,"completion":1108,"start":407,"enrollment":468,"conditions":1136,"interventions":1137},[56],[21],[1089,1111],{"nctId":1139,"briefTitle":1140,"status":219,"phases":1141,"primaryCompletion":405,"completion":406,"start":407,"enrollment":1117,"conditions":1142,"interventions":1144},"NCT03781466","Effect of Cervical Cerclage With Vaginal Progesterone in Asymptomatic Twin Pregnancies With a Sonographic Short Cervix",[56],[1143],"Twin; Pregnancy, Affecting Fetus or Newborn",[1111],{"intervention":1146,"totalTrials":9,"cells":1147},"Esomeprazole",{"EARLY_PHASE1":1148,"PHASE1":1150,"PHASE2":1152,"PHASE3":1154,"PHASE4":1163,"NA":1165},{"trials":1149,"activeCount":63},[],{"trials":1151,"activeCount":63},[],{"trials":1153,"activeCount":63},[],{"trials":1155,"activeCount":63},[1156],{"nctId":1157,"briefTitle":1158,"status":219,"phases":1159,"primaryCompletion":933,"completion":934,"start":418,"enrollment":1160,"conditions":1161,"interventions":1162},"NCT03717740","Esomeprazole for the Prevention of Preeclampsia",[54],1000,[31],[1146],{"trials":1164,"activeCount":63},[],{"trials":1166,"activeCount":63},[1167],{"nctId":1168,"briefTitle":1169,"status":219,"phases":1170,"primaryCompletion":593,"completion":594,"start":418,"enrollment":696,"conditions":1171,"interventions":1172},"NCT03717701","Metformin and Esomeprazole in Treatment of Early Onset Preeclampsia",[56],[31],[1173,1174],"metformin","esomeprazole",{"intervention":786,"totalTrials":9,"cells":1176},{"EARLY_PHASE1":1177,"PHASE1":1179,"PHASE2":1181,"PHASE3":1183,"PHASE4":1185,"NA":1187},{"trials":1178,"activeCount":63},[],{"trials":1180,"activeCount":63},[],{"trials":1182,"activeCount":63},[],{"trials":1184,"activeCount":63},[],{"trials":1186,"activeCount":63},[],{"trials":1188,"activeCount":63},[1189,1198],{"nctId":1190,"briefTitle":1191,"status":219,"phases":1192,"primaryCompletion":476,"completion":428,"start":373,"enrollment":408,"conditions":1193,"interventions":1195},"NCT04506034","Lidocaine Patch Versus Intravenous Lidocaine in Pain Relief After Laparoscopy",[56],[1194],"Infertility",[1196,786,1197],"lidocaine patches","IV saline",{"nctId":780,"briefTitle":781,"status":219,"phases":1199,"primaryCompletion":524,"completion":783,"start":373,"enrollment":586,"conditions":1200,"interventions":1201},[56],[15],[751,786,787],{"intervention":886,"totalTrials":9,"cells":1203},{"EARLY_PHASE1":1204,"PHASE1":1206,"PHASE2":1208,"PHASE3":1210,"PHASE4":1212,"NA":1214},{"trials":1205,"activeCount":63},[],{"trials":1207,"activeCount":63},[],{"trials":1209,"activeCount":63},[],{"trials":1211,"activeCount":63},[],{"trials":1213,"activeCount":63},[],{"trials":1215,"activeCount":63},[1216,1220],{"nctId":880,"briefTitle":881,"status":255,"phases":1217,"primaryCompletion":883,"completion":258,"start":407,"enrollment":408,"conditions":1218,"interventions":1219},[56],[26],[851,886,887],{"nctId":1221,"briefTitle":1222,"status":255,"phases":1223,"primaryCompletion":221,"completion":222,"start":1224,"enrollment":1225,"conditions":1226,"interventions":1228},"NCT05215158","Intravenous Versus Peribulbar Dexmedetomidine for Strabismus Surgery in Adults",[56],"2022-01-28",46,[1227],"Squint",[886],{"intervention":1230,"totalTrials":59,"cells":1231},"famotidine plus10ml normal saline",{"EARLY_PHASE1":1232,"PHASE1":1234,"PHASE2":1236,"PHASE3":1238,"PHASE4":1240,"NA":1242},{"trials":1233,"activeCount":63},[],{"trials":1235,"activeCount":63},[],{"trials":1237,"activeCount":63},[],{"trials":1239,"activeCount":63},[],{"trials":1241,"activeCount":63},[],{"trials":1243,"activeCount":63},[1244],{"nctId":1245,"briefTitle":1246,"status":255,"phases":1247,"primaryCompletion":1248,"completion":1249,"start":74,"enrollment":113,"conditions":1250,"interventions":1252},"NCT06211088","Famotidine Versus Placebo in Emergency Pediatric Surgery As a Risk to Postoperative Nausea and Vomiting",[56],"2024-12-30","2025-01-30",[1251],"Postoperative Nausea and Vomiting",[1230],{"intervention":1254,"totalTrials":59,"cells":1255},"bupivacaine with dexamethasone",{"EARLY_PHASE1":1256,"PHASE1":1258,"PHASE2":1260,"PHASE3":1262,"PHASE4":1264,"NA":1266},{"trials":1257,"activeCount":63},[],{"trials":1259,"activeCount":63},[],{"trials":1261,"activeCount":63},[],{"trials":1263,"activeCount":63},[],{"trials":1265,"activeCount":63},[],{"trials":1267,"activeCount":63},[1268],{"nctId":1269,"briefTitle":1270,"status":255,"phases":1271,"primaryCompletion":1272,"completion":1273,"start":161,"enrollment":595,"conditions":1274,"interventions":1275},"NCT06535256","Compare Intraperitoneal Instillation of Bupivacaine+dexmedetomidine Versus Bupivacaine+dexamethasone on Postoperative Pain After Lap Cholecystectomy",[56],"2024-11-10","2024-12-01",[26],[1254,1276],"bupivacaine with dexmedetomidine",{"intervention":1276,"totalTrials":59,"cells":1278},{"EARLY_PHASE1":1279,"PHASE1":1281,"PHASE2":1283,"PHASE3":1285,"PHASE4":1287,"NA":1289},{"trials":1280,"activeCount":63},[],{"trials":1282,"activeCount":63},[],{"trials":1284,"activeCount":63},[],{"trials":1286,"activeCount":63},[],{"trials":1288,"activeCount":63},[],{"trials":1290,"activeCount":63},[1291],{"nctId":1269,"briefTitle":1270,"status":255,"phases":1292,"primaryCompletion":1272,"completion":1273,"start":161,"enrollment":595,"conditions":1293,"interventions":1294},[56],[26],[1254,1276],{"intervention":1296,"totalTrials":59,"cells":1297},"diclofenac potassium + dinoprostone",{"EARLY_PHASE1":1298,"PHASE1":1300,"PHASE2":1302,"PHASE3":1304,"PHASE4":1306,"NA":1308},{"trials":1299,"activeCount":63},[],{"trials":1301,"activeCount":63},[],{"trials":1303,"activeCount":63},[],{"trials":1305,"activeCount":63},[],{"trials":1307,"activeCount":63},[],{"trials":1309,"activeCount":63},[1310],{"nctId":1311,"briefTitle":1312,"status":255,"phases":1313,"primaryCompletion":444,"completion":1314,"start":373,"enrollment":429,"conditions":1315,"interventions":1316},"NCT04500509","Diclofenac Potassium With or Without Vaginal Dinoprostone Prior to Hysterosalpingography",[56],"2021-10-30",[23],[1296,1317],"diclofenac potassium + placebo",{"intervention":1317,"totalTrials":59,"cells":1319},{"EARLY_PHASE1":1320,"PHASE1":1322,"PHASE2":1324,"PHASE3":1326,"PHASE4":1328,"NA":1330},{"trials":1321,"activeCount":63},[],{"trials":1323,"activeCount":63},[],{"trials":1325,"activeCount":63},[],{"trials":1327,"activeCount":63},[],{"trials":1329,"activeCount":63},[],{"trials":1331,"activeCount":63},[1332],{"nctId":1311,"briefTitle":1312,"status":255,"phases":1333,"primaryCompletion":444,"completion":1314,"start":373,"enrollment":429,"conditions":1334,"interventions":1335},[56],[23],[1296,1317],{"intervention":1057,"totalTrials":59,"cells":1337},{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1342,"PHASE3":1344,"PHASE4":1346,"NA":1348},{"trials":1339,"activeCount":63},[],{"trials":1341,"activeCount":63},[],{"trials":1343,"activeCount":63},[],{"trials":1345,"activeCount":63},[],{"trials":1347,"activeCount":63},[],{"trials":1349,"activeCount":63},[1350],{"nctId":1051,"briefTitle":1052,"status":255,"phases":1351,"primaryCompletion":372,"completion":1054,"start":373,"enrollment":408,"conditions":1352,"interventions":1353},[56],[18],[1057,1058,1036],{"intervention":1058,"totalTrials":59,"cells":1355},{"EARLY_PHASE1":1356,"PHASE1":1358,"PHASE2":1360,"PHASE3":1362,"PHASE4":1364,"NA":1366},{"trials":1357,"activeCount":63},[],{"trials":1359,"activeCount":63},[],{"trials":1361,"activeCount":63},[],{"trials":1363,"activeCount":63},[],{"trials":1365,"activeCount":63},[],{"trials":1367,"activeCount":63},[1368],{"nctId":1051,"briefTitle":1052,"status":255,"phases":1369,"primaryCompletion":372,"completion":1054,"start":373,"enrollment":408,"conditions":1370,"interventions":1371},[56],[18],[1057,1058,1036],{"intervention":1373,"totalTrials":59,"cells":1374},"Hyperbaric oxygen therapy",{"EARLY_PHASE1":1375,"PHASE1":1377,"PHASE2":1379,"PHASE3":1381,"PHASE4":1383,"NA":1385},{"trials":1376,"activeCount":63},[],{"trials":1378,"activeCount":63},[],{"trials":1380,"activeCount":63},[],{"trials":1382,"activeCount":63},[],{"trials":1384,"activeCount":63},[],{"trials":1386,"activeCount":63},[1387],{"nctId":1388,"briefTitle":1389,"status":255,"phases":1390,"primaryCompletion":1391,"completion":1391,"start":1392,"enrollment":1393,"conditions":1394,"interventions":1396},"NCT05152511","Management of Post-circumcision Ischemia Using Hyperbaric Oxygen Therapy",[],"2020-10-30","2017-04-01",23,[1395],"Post-circumsion Complications",[1373],{"intervention":433,"totalTrials":59,"cells":1398},{"EARLY_PHASE1":1399,"PHASE1":1401,"PHASE2":1403,"PHASE3":1405,"PHASE4":1407,"NA":1409},{"trials":1400,"activeCount":63},[],{"trials":1402,"activeCount":63},[],{"trials":1404,"activeCount":63},[],{"trials":1406,"activeCount":63},[],{"trials":1408,"activeCount":63},[],{"trials":1410,"activeCount":63},[1411],{"nctId":424,"briefTitle":425,"status":219,"phases":1412,"primaryCompletion":427,"completion":428,"start":373,"enrollment":429,"conditions":1413,"interventions":1414},[56],[18],[432,433,382],{"intervention":1416,"totalTrials":59,"cells":1417},"20 mL of bupivacaine 0.25%",{"EARLY_PHASE1":1418,"PHASE1":1420,"PHASE2":1422,"PHASE3":1424,"PHASE4":1426,"NA":1428},{"trials":1419,"activeCount":63},[],{"trials":1421,"activeCount":63},[],{"trials":1423,"activeCount":63},[],{"trials":1425,"activeCount":63},[],{"trials":1427,"activeCount":63},[],{"trials":1429,"activeCount":63},[1430],{"nctId":1431,"briefTitle":1432,"status":255,"phases":1433,"primaryCompletion":594,"completion":444,"start":567,"enrollment":696,"conditions":1434,"interventions":1435},"NCT03498118","Transversus Abdominis Plane Block Versus Wound Infiltration for Analgesia After Cesarean Delivery",[56],[870],[1416],{"intervention":1437,"totalTrials":59,"cells":1438},"Levobupivacaine",{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1443,"PHASE3":1445,"PHASE4":1447,"NA":1449},{"trials":1440,"activeCount":63},[],{"trials":1442,"activeCount":63},[],{"trials":1444,"activeCount":63},[],{"trials":1446,"activeCount":63},[],{"trials":1448,"activeCount":63},[],{"trials":1450,"activeCount":63},[1451],{"nctId":1452,"briefTitle":1453,"status":255,"phases":1454,"primaryCompletion":1455,"completion":1456,"start":1392,"enrollment":1457,"conditions":1458,"interventions":1463},"NCT04729868","Ultrasound Guided Infraclavicular Brachial Plexus Block Using Levo-bupivacaine Alone or Combined With Dexmedetomidine for Hand and Forearm Surgeries",[56],"2020-04-01","2020-10-01",60,[1459,1460,1461,1462],"Acquired Deformity of Elbow","Forearm","Hand","Wrist",[1437],{"intervention":1465,"totalTrials":59,"cells":1466},"sublingual misoprostol",{"EARLY_PHASE1":1467,"PHASE1":1469,"PHASE2":1471,"PHASE3":1473,"PHASE4":1475,"NA":1477},{"trials":1468,"activeCount":63},[],{"trials":1470,"activeCount":63},[],{"trials":1472,"activeCount":63},[],{"trials":1474,"activeCount":63},[],{"trials":1476,"activeCount":63},[],{"trials":1478,"activeCount":63},[1479],{"nctId":1480,"briefTitle":1481,"status":219,"phases":1482,"primaryCompletion":1483,"completion":1484,"start":458,"enrollment":429,"conditions":1485,"interventions":1487},"NCT05088707","Sublingual Versus Vaginal Misoprostol In Medical Treatment of Second Trimestric Missed Miscarriage",[56],"2022-12-31","2023-03-31",[1486],"Miscarriage",[1465,1488],"vaginal misoprostol",{"intervention":1488,"totalTrials":59,"cells":1490},{"EARLY_PHASE1":1491,"PHASE1":1493,"PHASE2":1495,"PHASE3":1497,"PHASE4":1499,"NA":1501},{"trials":1492,"activeCount":63},[],{"trials":1494,"activeCount":63},[],{"trials":1496,"activeCount":63},[],{"trials":1498,"activeCount":63},[],{"trials":1500,"activeCount":63},[],{"trials":1502,"activeCount":63},[1503],{"nctId":1480,"briefTitle":1481,"status":219,"phases":1504,"primaryCompletion":1483,"completion":1484,"start":458,"enrollment":429,"conditions":1505,"interventions":1506},[56],[1486],[1465,1488],{"intervention":1508,"totalTrials":59,"cells":1509},"misoprostol 800 µg",{"EARLY_PHASE1":1510,"PHASE1":1512,"PHASE2":1514,"PHASE3":1516,"PHASE4":1518,"NA":1520},{"trials":1511,"activeCount":63},[],{"trials":1513,"activeCount":63},[],{"trials":1515,"activeCount":63},[],{"trials":1517,"activeCount":63},[],{"trials":1519,"activeCount":63},[],{"trials":1521,"activeCount":63},[1522],{"nctId":1523,"briefTitle":1524,"status":219,"phases":1525,"primaryCompletion":1483,"completion":1484,"start":458,"enrollment":429,"conditions":1526,"interventions":1527},"NCT05088720","Misoprostol for Management of Women With an Incomplete Miscarriage",[56],[1486],[1508,1528],"misoprostol 400 µg",{"intervention":1528,"totalTrials":59,"cells":1530},{"EARLY_PHASE1":1531,"PHASE1":1533,"PHASE2":1535,"PHASE3":1537,"PHASE4":1539,"NA":1541},{"trials":1532,"activeCount":63},[],{"trials":1534,"activeCount":63},[],{"trials":1536,"activeCount":63},[],{"trials":1538,"activeCount":63},[],{"trials":1540,"activeCount":63},[],{"trials":1542,"activeCount":63},[1543],{"nctId":1523,"briefTitle":1524,"status":219,"phases":1544,"primaryCompletion":1483,"completion":1484,"start":458,"enrollment":429,"conditions":1545,"interventions":1546},[56],[1486],[1508,1528],{"intervention":1548,"totalTrials":59,"cells":1549},"progesterone 400mg",{"EARLY_PHASE1":1550,"PHASE1":1552,"PHASE2":1554,"PHASE3":1556,"PHASE4":1558,"NA":1560},{"trials":1551,"activeCount":63},[],{"trials":1553,"activeCount":63},[],{"trials":1555,"activeCount":63},[],{"trials":1557,"activeCount":63},[],{"trials":1559,"activeCount":63},[],{"trials":1561,"activeCount":63},[1562],{"nctId":1563,"briefTitle":1564,"status":219,"phases":1565,"primaryCompletion":1107,"completion":1116,"start":407,"enrollment":429,"conditions":1566,"interventions":1567},"NCT03781674","Role of 200 mg Versus 400mg Vaginal Progesterone in Prevention of Preterm Labor in Twin Gestation",[56],[1143],[1548,1568],"progesterone 200mg",{"intervention":1568,"totalTrials":59,"cells":1570},{"EARLY_PHASE1":1571,"PHASE1":1573,"PHASE2":1575,"PHASE3":1577,"PHASE4":1579,"NA":1581},{"trials":1572,"activeCount":63},[],{"trials":1574,"activeCount":63},[],{"trials":1576,"activeCount":63},[],{"trials":1578,"activeCount":63},[],{"trials":1580,"activeCount":63},[],{"trials":1582,"activeCount":63},[1583],{"nctId":1563,"briefTitle":1564,"status":219,"phases":1584,"primaryCompletion":1107,"completion":1116,"start":407,"enrollment":429,"conditions":1585,"interventions":1586},[56],[1143],[1548,1568],{"intervention":536,"totalTrials":59,"cells":1588},{"EARLY_PHASE1":1589,"PHASE1":1591,"PHASE2":1593,"PHASE3":1595,"PHASE4":1597,"NA":1599},{"trials":1590,"activeCount":63},[],{"trials":1592,"activeCount":63},[],{"trials":1594,"activeCount":63},[],{"trials":1596,"activeCount":63},[],{"trials":1598,"activeCount":63},[],{"trials":1600,"activeCount":63},[1601],{"nctId":529,"briefTitle":530,"status":255,"phases":1602,"primaryCompletion":484,"completion":258,"start":532,"enrollment":533,"conditions":1603,"interventions":1604},[56],[15],[451,462,536],{"intervention":749,"totalTrials":59,"cells":1606},{"EARLY_PHASE1":1607,"PHASE1":1609,"PHASE2":1611,"PHASE3":1613,"PHASE4":1615,"NA":1617},{"trials":1608,"activeCount":63},[],{"trials":1610,"activeCount":63},[],{"trials":1612,"activeCount":63},[],{"trials":1614,"activeCount":63},[],{"trials":1616,"activeCount":63},[],{"trials":1618,"activeCount":63},[1619],{"nctId":742,"briefTitle":743,"status":219,"phases":1620,"primaryCompletion":493,"completion":745,"start":373,"enrollment":429,"conditions":1621,"interventions":1622},[56],[747],[700,749],{"intervention":1624,"totalTrials":59,"cells":1625},"IV tranexamic acid",{"EARLY_PHASE1":1626,"PHASE1":1628,"PHASE2":1630,"PHASE3":1632,"PHASE4":1634,"NA":1636},{"trials":1627,"activeCount":63},[],{"trials":1629,"activeCount":63},[],{"trials":1631,"activeCount":63},[],{"trials":1633,"activeCount":63},[],{"trials":1635,"activeCount":63},[],{"trials":1637,"activeCount":63},[1638],{"nctId":1639,"briefTitle":1640,"status":255,"phases":1641,"primaryCompletion":1642,"completion":1643,"start":567,"enrollment":696,"conditions":1644,"interventions":1645},"NCT03505502","Reducing Blood Loss During Cesarean Myomectomy With Tranexamic Acid",[56],"2020-01-01","2020-03-01",[15],[1624],{"intervention":1647,"totalTrials":59,"cells":1648},"Topical TA",{"EARLY_PHASE1":1649,"PHASE1":1651,"PHASE2":1653,"PHASE3":1655,"PHASE4":1657,"NA":1659},{"trials":1650,"activeCount":63},[],{"trials":1652,"activeCount":63},[],{"trials":1654,"activeCount":63},[],{"trials":1656,"activeCount":63},[],{"trials":1658,"activeCount":63},[],{"trials":1660,"activeCount":63},[1661],{"nctId":1662,"briefTitle":1663,"status":219,"phases":1664,"primaryCompletion":524,"completion":1665,"start":446,"enrollment":595,"conditions":1666,"interventions":1667},"NCT03880045","Topical Tranexamic Acid Plus Perivascular Vasopressin at the Time of Abdominal Myomectomy",[56],"2021-06-01",[689],[1647,1668],"vasopressin",{"intervention":1668,"totalTrials":59,"cells":1670},{"EARLY_PHASE1":1671,"PHASE1":1673,"PHASE2":1675,"PHASE3":1677,"PHASE4":1679,"NA":1681},{"trials":1672,"activeCount":63},[],{"trials":1674,"activeCount":63},[],{"trials":1676,"activeCount":63},[],{"trials":1678,"activeCount":63},[],{"trials":1680,"activeCount":63},[],{"trials":1682,"activeCount":63},[1683],{"nctId":1662,"briefTitle":1663,"status":219,"phases":1684,"primaryCompletion":524,"completion":1665,"start":446,"enrollment":595,"conditions":1685,"interventions":1686},[56],[689],[1647,1668],{"intervention":1688,"totalTrials":59,"cells":1689},"preoperative carbohydrate loading",{"EARLY_PHASE1":1690,"PHASE1":1692,"PHASE2":1694,"PHASE3":1696,"PHASE4":1698,"NA":1700},{"trials":1691,"activeCount":63},[],{"trials":1693,"activeCount":63},[],{"trials":1695,"activeCount":63},[],{"trials":1697,"activeCount":63},[],{"trials":1699,"activeCount":63},[],{"trials":1701,"activeCount":63},[1702],{"nctId":1703,"briefTitle":1704,"status":255,"phases":1705,"primaryCompletion":372,"completion":444,"start":418,"enrollment":429,"conditions":1706,"interventions":1707},"NCT03732404","Oral Preoperative Carbohydrate on Early Postoperative Outcome After Cesarean Section",[56],[15],[1688],{"intervention":1709,"totalTrials":59,"cells":1710},"Oxygen",{"EARLY_PHASE1":1711,"PHASE1":1713,"PHASE2":1715,"PHASE3":1717,"PHASE4":1719,"NA":1721},{"trials":1712,"activeCount":63},[],{"trials":1714,"activeCount":63},[],{"trials":1716,"activeCount":63},[],{"trials":1718,"activeCount":63},[],{"trials":1720,"activeCount":63},[],{"trials":1722,"activeCount":63},[1723],{"nctId":1724,"briefTitle":1725,"status":255,"phases":1726,"primaryCompletion":1727,"completion":1728,"start":1729,"enrollment":1730,"conditions":1731,"interventions":1733},"NCT04824703","Comparative Study Between Liberal and Conservative Oxygen Therapy in Mechanically Ventilated Intensive Care Patients",[56],"2023-05-05","2023-05-11","2021-04-05",106,[1732],"Oxygen Therapy",[1709],{"intervention":1735,"totalTrials":59,"cells":1736},"L-arginine 5 gm oral caps",{"EARLY_PHASE1":1737,"PHASE1":1739,"PHASE2":1741,"PHASE3":1743,"PHASE4":1745,"NA":1747},{"trials":1738,"activeCount":63},[],{"trials":1740,"activeCount":63},[],{"trials":1742,"activeCount":63},[],{"trials":1744,"activeCount":63},[],{"trials":1746,"activeCount":63},[],{"trials":1748,"activeCount":63},[1749],{"nctId":1750,"briefTitle":1751,"status":255,"phases":1752,"primaryCompletion":1753,"completion":1753,"start":1754,"enrollment":1755,"conditions":1756,"interventions":1758},"NCT03834610","Daily Oral L-arginine Plus Tadalafil in Diabetic Patients With Erectile Dysfunction",[56],"2018-10-01","2017-10-01",108,[1757],"Erectile Dysfunction",[1735,1759],"Tadalafil 10 MG",{"intervention":1759,"totalTrials":59,"cells":1761},{"EARLY_PHASE1":1762,"PHASE1":1764,"PHASE2":1766,"PHASE3":1768,"PHASE4":1770,"NA":1772},{"trials":1763,"activeCount":63},[],{"trials":1765,"activeCount":63},[],{"trials":1767,"activeCount":63},[],{"trials":1769,"activeCount":63},[],{"trials":1771,"activeCount":63},[],{"trials":1773,"activeCount":63},[1774],{"nctId":1750,"briefTitle":1751,"status":255,"phases":1775,"primaryCompletion":1753,"completion":1753,"start":1754,"enrollment":1755,"conditions":1776,"interventions":1777},[56],[1757],[1735,1759],{"intervention":1196,"totalTrials":59,"cells":1779},{"EARLY_PHASE1":1780,"PHASE1":1782,"PHASE2":1784,"PHASE3":1786,"PHASE4":1788,"NA":1790},{"trials":1781,"activeCount":63},[],{"trials":1783,"activeCount":63},[],{"trials":1785,"activeCount":63},[],{"trials":1787,"activeCount":63},[],{"trials":1789,"activeCount":63},[],{"trials":1791,"activeCount":63},[1792],{"nctId":1190,"briefTitle":1191,"status":219,"phases":1793,"primaryCompletion":476,"completion":428,"start":373,"enrollment":408,"conditions":1794,"interventions":1795},[56],[1194],[1196,786,1197],{"intervention":1197,"totalTrials":59,"cells":1797},{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1802,"PHASE3":1804,"PHASE4":1806,"NA":1808},{"trials":1799,"activeCount":63},[],{"trials":1801,"activeCount":63},[],{"trials":1803,"activeCount":63},[],{"trials":1805,"activeCount":63},[],{"trials":1807,"activeCount":63},[],{"trials":1809,"activeCount":63},[1810],{"nctId":1190,"briefTitle":1191,"status":219,"phases":1811,"primaryCompletion":476,"completion":428,"start":373,"enrollment":408,"conditions":1812,"interventions":1813},[56],[1194],[1196,786,1197],{"intervention":887,"totalTrials":59,"cells":1815},{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1820,"PHASE3":1822,"PHASE4":1824,"NA":1826},{"trials":1817,"activeCount":63},[],{"trials":1819,"activeCount":63},[],{"trials":1821,"activeCount":63},[],{"trials":1823,"activeCount":63},[],{"trials":1825,"activeCount":63},[],{"trials":1827,"activeCount":63},[1828],{"nctId":880,"briefTitle":881,"status":255,"phases":1829,"primaryCompletion":883,"completion":258,"start":407,"enrollment":408,"conditions":1830,"interventions":1831},[56],[26],[851,886,887],{"intervention":479,"totalTrials":59,"cells":1833},{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1838,"PHASE3":1840,"PHASE4":1842,"NA":1844},{"trials":1835,"activeCount":63},[],{"trials":1837,"activeCount":63},[],{"trials":1839,"activeCount":63},[],{"trials":1841,"activeCount":63},[],{"trials":1843,"activeCount":63},[],{"trials":1845,"activeCount":63},[1846],{"nctId":473,"briefTitle":474,"status":219,"phases":1847,"primaryCompletion":372,"completion":476,"start":373,"enrollment":429,"conditions":1848,"interventions":1849},[56],[18],[479,382],{"intervention":1851,"totalTrials":59,"cells":1852},"Esomeprazole with Sildenafil Citrate",{"EARLY_PHASE1":1853,"PHASE1":1855,"PHASE2":1857,"PHASE3":1859,"PHASE4":1861,"NA":1863},{"trials":1854,"activeCount":63},[],{"trials":1856,"activeCount":63},[],{"trials":1858,"activeCount":63},[],{"trials":1860,"activeCount":63},[],{"trials":1862,"activeCount":63},[],{"trials":1864,"activeCount":63},[1865],{"nctId":1866,"briefTitle":1867,"status":219,"phases":1868,"primaryCompletion":933,"completion":934,"start":418,"enrollment":586,"conditions":1869,"interventions":1870},"NCT03724838","Esomeprazole With Sildenafil Citrate in Women With Early-onset Preeclampsia",[56],[29],[1851,1871],"Sildenafil Citrate",{"intervention":1871,"totalTrials":59,"cells":1873},{"EARLY_PHASE1":1874,"PHASE1":1876,"PHASE2":1878,"PHASE3":1880,"PHASE4":1882,"NA":1884},{"trials":1875,"activeCount":63},[],{"trials":1877,"activeCount":63},[],{"trials":1879,"activeCount":63},[],{"trials":1881,"activeCount":63},[],{"trials":1883,"activeCount":63},[],{"trials":1885,"activeCount":63},[1886],{"nctId":1866,"briefTitle":1867,"status":219,"phases":1887,"primaryCompletion":933,"completion":934,"start":418,"enrollment":586,"conditions":1888,"interventions":1889},[56],[29],[1851,1871],{"intervention":787,"totalTrials":59,"cells":1891},{"EARLY_PHASE1":1892,"PHASE1":1894,"PHASE2":1896,"PHASE3":1898,"PHASE4":1900,"NA":1902},{"trials":1893,"activeCount":63},[],{"trials":1895,"activeCount":63},[],{"trials":1897,"activeCount":63},[],{"trials":1899,"activeCount":63},[],{"trials":1901,"activeCount":63},[],{"trials":1903,"activeCount":63},[1904],{"nctId":780,"briefTitle":781,"status":219,"phases":1905,"primaryCompletion":524,"completion":783,"start":373,"enrollment":586,"conditions":1906,"interventions":1907},[56],[15],[751,786,787],{"intervention":1909,"totalTrials":59,"cells":1910},"Calcipotriol",{"EARLY_PHASE1":1911,"PHASE1":1913,"PHASE2":1915,"PHASE3":1917,"PHASE4":1919,"NA":1921},{"trials":1912,"activeCount":63},[],{"trials":1914,"activeCount":63},[],{"trials":1916,"activeCount":63},[],{"trials":1918,"activeCount":63},[],{"trials":1920,"activeCount":63},[],{"trials":1922,"activeCount":63},[1923],{"nctId":1924,"briefTitle":1925,"status":255,"phases":1926,"primaryCompletion":1927,"completion":1927,"start":1754,"enrollment":1457,"conditions":1928,"interventions":1930},"NCT03847441","Topical Calcipotriol Versus Narrowband Ultraviolet B in Treatment of Alopecia Areata",[56],"2018-12-31",[1929],"Alopecia Areata",[1909],{"intervention":1932,"totalTrials":59,"cells":1933},"Dexmedetomidine Hydrochloride",{"EARLY_PHASE1":1934,"PHASE1":1936,"PHASE2":1938,"PHASE3":1940,"PHASE4":1942,"NA":1944},{"trials":1935,"activeCount":63},[],{"trials":1937,"activeCount":63},[],{"trials":1939,"activeCount":63},[],{"trials":1941,"activeCount":63},[],{"trials":1943,"activeCount":63},[],{"trials":1945,"activeCount":63},[1946],{"nctId":1947,"briefTitle":1948,"status":255,"phases":1949,"primaryCompletion":1950,"completion":1951,"start":1952,"enrollment":1953,"conditions":1954,"interventions":1956},"NCT05175781","Sedation for Non-invasive Ventilation in Blunt Chest Trauma",[56],"2022-07-20","2022-07-26","2022-01-18",45,[1955],"Chest Trauma",[1932,1957],"Ketamine Hydrochloride",{"intervention":1957,"totalTrials":59,"cells":1959},{"EARLY_PHASE1":1960,"PHASE1":1962,"PHASE2":1964,"PHASE3":1966,"PHASE4":1968,"NA":1970},{"trials":1961,"activeCount":63},[],{"trials":1963,"activeCount":63},[],{"trials":1965,"activeCount":63},[],{"trials":1967,"activeCount":63},[],{"trials":1969,"activeCount":63},[],{"trials":1971,"activeCount":63},[1972],{"nctId":1947,"briefTitle":1948,"status":255,"phases":1973,"primaryCompletion":1950,"completion":1951,"start":1952,"enrollment":1953,"conditions":1974,"interventions":1975},[56],[1955],[1932,1957],{"intervention":1977,"totalTrials":59,"cells":1978},"Intramyometrial Vasopressin",{"EARLY_PHASE1":1979,"PHASE1":1981,"PHASE2":1983,"PHASE3":1985,"PHASE4":1987,"NA":1989},{"trials":1980,"activeCount":63},[],{"trials":1982,"activeCount":63},[],{"trials":1984,"activeCount":63},[],{"trials":1986,"activeCount":63},[],{"trials":1988,"activeCount":63},[],{"trials":1990,"activeCount":63},[1991],{"nctId":1992,"briefTitle":1993,"status":255,"phases":1994,"primaryCompletion":372,"completion":444,"start":418,"enrollment":696,"conditions":1995,"interventions":1996},"NCT03725553","Intra-myometrial Vasopressin During Cesarean Section in Placenta Previa",[56],[21],[1977],{"intervention":1998,"totalTrials":59,"cells":1999},"Ketoprofen + INH",{"EARLY_PHASE1":2000,"PHASE1":2002,"PHASE2":2004,"PHASE3":2006,"PHASE4":2008,"NA":2010},{"trials":2001,"activeCount":63},[],{"trials":2003,"activeCount":63},[],{"trials":2005,"activeCount":63},[],{"trials":2007,"activeCount":63},[],{"trials":2009,"activeCount":63},[],{"trials":2011,"activeCount":63},[2012],{"nctId":2013,"briefTitle":2014,"status":255,"phases":2015,"primaryCompletion":427,"completion":445,"start":373,"enrollment":429,"conditions":2016,"interventions":2017},"NCT04500470","Ketoprofen With or Without Vaginal Isonicotinic Acid Hydrazide Prior to Hysterosalpingography",[56],[23],[1998,2018],"Ketoprofen + placebo",{"intervention":2018,"totalTrials":59,"cells":2020},{"EARLY_PHASE1":2021,"PHASE1":2023,"PHASE2":2025,"PHASE3":2027,"PHASE4":2029,"NA":2031},{"trials":2022,"activeCount":63},[],{"trials":2024,"activeCount":63},[],{"trials":2026,"activeCount":63},[],{"trials":2028,"activeCount":63},[],{"trials":2030,"activeCount":63},[],{"trials":2032,"activeCount":63},[2033],{"nctId":2013,"briefTitle":2014,"status":255,"phases":2034,"primaryCompletion":427,"completion":445,"start":373,"enrollment":429,"conditions":2035,"interventions":2036},[56],[23],[1998,2018],{"intervention":2038,"totalTrials":59,"cells":2039},"Deferoxamine",{"EARLY_PHASE1":2040,"PHASE1":2042,"PHASE2":2044,"PHASE3":2046,"PHASE4":2048,"NA":2050},{"trials":2041,"activeCount":63},[],{"trials":2043,"activeCount":63},[],{"trials":2045,"activeCount":63},[],{"trials":2047,"activeCount":63},[],{"trials":2049,"activeCount":63},[],{"trials":2051,"activeCount":63},[2052],{"nctId":2053,"briefTitle":2054,"status":255,"phases":2055,"primaryCompletion":2056,"completion":2057,"start":2058,"enrollment":2059,"conditions":2060,"interventions":2062},"NCT05748587","Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in Ischemic Stroke",[],"2024-03-01","2024-04-01","2023-04-01",48,[2061],"Brain Ischemia",[2038],{"intervention":1173,"totalTrials":59,"cells":2064},{"EARLY_PHASE1":2065,"PHASE1":2067,"PHASE2":2069,"PHASE3":2071,"PHASE4":2073,"NA":2075},{"trials":2066,"activeCount":63},[],{"trials":2068,"activeCount":63},[],{"trials":2070,"activeCount":63},[],{"trials":2072,"activeCount":63},[],{"trials":2074,"activeCount":63},[],{"trials":2076,"activeCount":63},[2077],{"nctId":1168,"briefTitle":1169,"status":219,"phases":2078,"primaryCompletion":593,"completion":594,"start":418,"enrollment":696,"conditions":2079,"interventions":2080},[56],[31],[1173,1174],{"intervention":547,"totalTrials":59,"cells":2082},{"EARLY_PHASE1":2083,"PHASE1":2085,"PHASE2":2087,"PHASE3":2089,"PHASE4":2091,"NA":2093},{"trials":2084,"activeCount":63},[],{"trials":2086,"activeCount":63},[],{"trials":2088,"activeCount":63},[],{"trials":2090,"activeCount":63},[],{"trials":2092,"activeCount":63},[],{"trials":2094,"activeCount":63},[2095],{"nctId":542,"briefTitle":543,"status":255,"phases":2096,"primaryCompletion":372,"completion":444,"start":446,"enrollment":447,"conditions":2097,"interventions":2098},[56],[33],[462,547,451]]